Research programme: type 2 diabetes mellitus therapeutic - CamurusAlternative Names: CAM 2036
Latest Information Update: 04 May 2016
At a glance
- Originator Camurus
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 04 May 2016 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route)
- 01 Jan 2014 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)